반응식
[CH:1]1([C:4]2[N:9]=[C:8]([C:10]([OH:12])=O)[C:7]([NH:13][C:14]3[CH:15]=[N:16][CH:17]=[CH:18][CH:19]=3)=[N:6][CH:5]=2)[CH2:3][CH2:2]1.[NH2:20][C:21]1[CH:25]=[N:24][N:23]([CH3:26])[C:22]=1[C:27]([N:29]1[CH2:32][CH2:31][CH2:30]1)=[O:28]>>[N:29]1([C:27]([C:22]2[N:23]([CH3:26])[N:24]=[CH:25][C:21]=2[NH:20][C:10]([C:8]2[C:7]([NH:13][C:14]3[CH:15]=[N:16][CH:17]=[CH:18][CH:19]=3)=[N:6][CH:5]=[C:4]([CH:1]3[CH2:2][CH2:3]3)[N:9]=2)=[O:12])=[O:28])[CH2:30][CH2:31][CH2:32]1참가 물질
3
실험 절차
The product was obtained starting from 6-cyclopropyl-3-(pyridin-3-ylamino)pyrazine-2-carboxylic acid (30 mg, 0.12 mmol; example 217, step 2) and (4-amino-2-methyl-2H-pyrazol-3-yl)-azetidin-1-yl-methanone (27 mg, 0.15 mmol) according to the method described in example 64, step 6 after purification by preparative HPLC using an acetonitrile/water gradient as light yellow solid (37 mg, 75%).
후처리
- customThe product was obtained
- customafter purification by preparative HPLC
출처 및 근거
- ORD 기록
- ord-951730cb24314134811a636508b0fcef
- 출처 데이터셋
- uspto-grants-2014_04
- 특허 번호
- US08703768B2
연결된 노트
불러오는 중…